Insmed reported $-29959000 in Equity Capital and Reserves for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
DBV Technologies DBVT:US USD 212.05M 32.36M
Acelrx Pharmaceuticals ACRX:US USD 27.54M 5.6M
Alimera Sciences ALIM:US USD -18078000 5.74M
Biomarin Pharmaceutical BMRN:US USD 4.57B 63.71M
Cytokinetics CYTK:US USD -15977000 127.39M
Gilead Sciences GILD:US USD 21.06B 821M
Heron Therapeutics HRTX:US USD 22.45M 44.19M
Insmed INSM:US USD -29959000 74.2M
Mirati Therapeutics MRTX:US USD 1.13B 17.05M
Novartis NVS:US USD 60.82B 2.1B
Ophthotech OPHT:US USD 259.53M 33.42M
Regeneron Pharmaceuticals REGN:US USD 21.44B 751M
Sarepta Therapeutics SRPT:US USD 430.84M 295.62M
Seattle Genetics SGEN:US USD 2.82B 111M
Ultragenyx Pharmaceutical RARE:US USD 468.83M 209.24M
Vertex Pharmaceuticals VRTX:US USD 13.03B 1.1B